How Much BAC Water for Cagrilintide? Research Reconstitution & Concentration Guide
For a lyophilized cagrilintide research material, the amount of bacteriostatic water used determines the final laboratory concentration. The governing calculation is total compound quantity ÷ final liquid volume = concentration. Cagrilintide remains investigational, so there is no FDA-approved cagrilintide label establishing one universal BAC-water reconstitution volume.
Recommended Cagrilintide Research Concentration Formulas
There is no single universal BAC-water volume for every cagrilintide research vial. A practical laboratory approach is to select a target concentration that makes calculations reproducible, then calculate the final liquid volume from the vial quantity.
Final concentration (mg/mL) = cagrilintide quantity (mg) ÷ final liquid volume (mL) Required final liquid volume (mL) = cagrilintide quantity (mg) ÷ target concentration (mg/mL)Quick Reference: Cagrilintide + BAC Water Research Concentrations
The examples below produce simple mathematical concentrations for laboratory reference. They are not FDA-approved or clinically validated cagrilintide preparation procedures.
| Cagrilintide research vial | Example final liquid volume | Calculated concentration | Research-use rationale |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | Compact whole-number concentration. |
| 5 mg | 2 mL | 2.5 mg/mL | Simple lower-concentration reference. |
| 10 mg | 2 mL | 5 mg/mL | Matches the 5 mg/mL reference concentration. |
| 10 mg | 4 mL | 2.5 mg/mL | Matches the 2.5 mg/mL reference concentration. |
| 15 mg | 3 mL | 5 mg/mL | Whole-number 5 mg/mL concentration. |
| 15 mg | 6 mL | 2.5 mg/mL | Mathematical example; actual vial capacity must be verified. |
| 30 mg | 6 mL | 5 mg/mL | Simple high-quantity reference. |
Cagrilintide BAC Water Calculator
Calculate mathematical liquid volume and concentration from a research vial quantity.
How Much BAC Water for Common Cagrilintide Research Vial Sizes?
5 mg Cagrilintide Research Vial
| Final liquid volume | Calculated concentration |
|---|---|
| 1 mL | 5 mg/mL |
| 2 mL | 2.5 mg/mL |
| 2.5 mL | 2 mg/mL |
| 5 mL | 1 mg/mL |
10 mg Cagrilintide Research Vial
| Final liquid volume | Calculated concentration |
|---|---|
| 1 mL | 10 mg/mL |
| 2 mL | 5 mg/mL |
| 4 mL | 2.5 mg/mL |
| 5 mL | 2 mg/mL |
15 mg Cagrilintide Research Vial
| Final liquid volume | Calculated concentration |
|---|---|
| 1.5 mL | 10 mg/mL |
| 3 mL | 5 mg/mL |
| 6 mL | 2.5 mg/mL |
| 7.5 mL | 2 mg/mL |
These tables show concentration mathematics only. No syringe-unit conversions, human dose calculations, injection volumes, or administration instructions are provided.
Clinical Research Snapshot
What Is Cagrilintide?
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone involved in appetite, gastric emptying and glucose regulation. It has been studied as a standalone investigational compound and in combination with semaglutide.
Unlike semaglutide, cagrilintide is not a GLP-1 receptor agonist. Its amylin-related mechanism provides a distinct biological pathway for metabolic research.
Mechanism of Action
Cagrilintide is designed to reproduce important biological effects associated with amylin signaling while providing prolonged activity suitable for once-weekly clinical study protocols.
FDA / Regulatory Status
Cagrilintide remains investigational and is not FDA approved.
FDA states that cagrilintide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. FDA also states that cagrilintide cannot be used in compounding under federal law.
Major Human Clinical Trials
| Study | Phase | Population | Doses / regimen | Key research point | Source |
|---|---|---|---|---|---|
| Phase 2 Dose-Finding NCT03856047 | 2 | Adults with overweight or obesity without diabetes | 0.3, 0.6, 1.2, 2.4, 4.5 mg weekly | Evaluated dose response, body weight, safety and tolerability. | PubMed |
| Cagrilintide + Semaglutide NCT03845166 | 1b | Adults with overweight or obesity | Ascending cagrilintide doses with semaglutide | Evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of combination therapy. | PubMed |
| REDEFINE 1 | 3 | Overweight or obesity without diabetes | Cagrilintide 2.4 mg; CagriSema 2.4/2.4 mg | Large phase 3 weight-management study including cagrilintide and combination arms. | PubMed |
| REDEFINE 2 | 3 | Overweight or obesity with type 2 diabetes | CagriSema 2.4/2.4 mg | Evaluated weight and glycemic outcomes over 68 weeks. | PubMed |
| REDEFINE 5 | 3a | Adults in Japan and Taiwan with overweight or obesity, with or without type 2 diabetes | Cagrilintide-semaglutide vs semaglutide | Published 2026 phase 3a evidence in an East Asian population. | PubMed |
| REIMAGINE 2 | 3 | People with type 2 diabetes | CagriSema vs semaglutide or cagrilintide | Published 2026 phase 3 evidence directly comparing combination and component arms. | PubMed |
Doses Studied in Cagrilintide Clinical Research
Clinical studies have evaluated multiple cagrilintide quantities, including 0.3, 0.6, 1.2, 2.4 and 4.5 mg in phase 2 dose-finding work, as well as 2.4 mg in later combination-development programs.
Cagrilintide Research Outcomes
Dose-Response Research
Phase 2 research evaluated cagrilintide across multiple dose groups to characterize weight-related outcomes, tolerability and dose-response relationships.
Cagrilintide + Semaglutide
Large phase 3 studies have evaluated the combination of cagrilintide and semaglutide (CagriSema), including REDEFINE and REIMAGINE programs. Combination results should not be attributed entirely to cagrilintide because semaglutide is an active component.
2026 REDEFINE 5
REDEFINE 5 reported significantly greater body-weight reduction with cagrilintide-semaglutide than semaglutide alone in adults from Japan and Taiwan with overweight or obesity.
Adverse Events & Safety Findings
Gastrointestinal adverse events—including nausea, vomiting, diarrhea and constipation—have been prominent in cagrilintide and CagriSema clinical research. Because cagrilintide remains investigational, its safety profile continues to be characterized through ongoing clinical development and regulatory review.
Research Limitations & What Remains Unknown
Cagrilintide Reconstitution & Research FAQ
How much BAC water should be used for Cagrilintide research?
There is no universal BAC-water volume for every cagrilintide research vial. The final liquid volume should be selected from the vial quantity and target laboratory concentration. Mathematically, liquid volume equals total compound quantity divided by desired concentration.
How much BAC water for a 5 mg Cagrilintide research vial?
As concentration mathematics, 5 mg with a final liquid volume of 1 mL equals 5 mg/mL; with 2 mL it equals 2.5 mg/mL; and with 2.5 mL it equals 2 mg/mL.
How much BAC water for a 10 mg Cagrilintide research vial?
Mathematically, 10 mg with 2 mL final liquid volume equals 5 mg/mL; 4 mL equals 2.5 mg/mL; and 5 mL equals 2 mg/mL.
How much BAC water for a 15 mg Cagrilintide research vial?
Mathematically, 15 mg with 3 mL final liquid volume equals 5 mg/mL; 6 mL equals 2.5 mg/mL; and 7.5 mL equals 2 mg/mL. Actual vial capacity must be verified.
How do you calculate Cagrilintide concentration?
Divide total cagrilintide quantity in milligrams by final liquid volume in milliliters. The result is the concentration in mg/mL.
Does adding more BAC water change the total amount of Cagrilintide?
No. In concentration mathematics, increasing liquid volume lowers the concentration while the total compound quantity remains unchanged.
Is Cagrilintide FDA approved?
No. Cagrilintide remains investigational and is not an FDA-approved drug.
Can Cagrilintide be compounded?
FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of an FDA-approved drug.
What is CagriSema?
CagriSema is the investigational combination of cagrilintide and semaglutide. Combination-trial results should be distinguished from cagrilintide monotherapy evidence.
Does this page provide Cagrilintide dosing information?
No. It provides research concentration mathematics and scientific reference information, not human dosing, syringe-unit conversions, injection instructions or treatment recommendations.
Scientific & Regulatory References
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA.
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a randomized dose-finding phase 2 trial. Lancet. PubMed.
- McFarlane J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide. Lancet. PubMed.
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. PubMed.
- Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. PubMed.
- Yamauchi T, et al. REDEFINE 5: cagrilintide-semaglutide versus semaglutide in adults with overweight or obesity in Japan and Taiwan. Lancet Diabetes Endocrinol. 2026. PubMed.
- Buse JB, et al. REIMAGINE 2: cagrilintide-semaglutide versus semaglutide or cagrilintide in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2026. PubMed.